Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

Medtronic plcMDT announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor (CGM) used with the MiniMed 670G insulin pump. Notably, the Guardian ...

The company's announcement notably does not use the term "artificial pancreas," although the technology is a considerably more significant advance from the 530G threshold suspend device of 2013. When ...

The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm. The sensor is part of Medtronic’s MiniMed 670G system, and is currently ...

WASHINGTON--Patients with type 1 diabetes who use Medtronic's MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a ...

Children with Type 1 diabetes will now have access to the Medtronic MiniMed 670G, a hybrid closed-loop system insulin delivery system, following the FDA’s decision to expand the product approval for a ...

Medtronic's MiniMed 670G could reduce the burden on Type 1 diabetes patients, as well as slow diabetes progression by keeping blood glucose levels on target. There are about 1.25 million Americans ...

In a recent press release, Medtronic announced that is has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system – the first and only system to automate and ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

The approval of Medtronic's Minimed 670G could reshape the type 1 treatment market next year, but I wouldn't count DexCom out. Its best-in-class technology could position it to capture a significant ...